A Phase 3 interventional study of Gynoclin V and Vagitrol V in Vaginitis and Infectious Vaginosis, sponsored by Janssen-Cilag, S.A.. Completed at 2 sites in Mexico. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2013-12-24.
Sponsored by Janssen-Cilag, S.A. (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this comparative study is to evaluate the efficacy of an ovule with triple active agents (terconazole, clindamycin and fluocinolone) versus another ovule with triple active agents (nystatin, metronidazole and fluocinolone) in the treatment of symptoms caused by the presence of vaginitis (inflammation of the vagina) or bacterial vaginosis (polymicrobial, nonspecific vaginitis associated with positive cultures of Gardnerella vaginalis and other anaerobic organisms and a decrease in lactobacilli).
This is a prospective (study following participants forward in time), open-label (all people know the identity of the intervention), randomized (the study drug is assigned by chance), comparative, parallel (a clinical trial comparing the response in 2 or more groups of participants receiving different treatments) double-arm, multi-center (when more than 1 hospital or medical school team work on a medical research study) study. The study consists of 3 phases: Screening phase on Visit 1 (Day -3/1); Inclusion or treatment phase on Visit 2 (Day 1); and Treatment or monitoring phase (3 days after treatment) on Visit 3 (Day 7 for Gynoclin V and Day 13 for Vagitrol V) and Visit 4 (Day 12 for Gynoclin V and Day 18 for Vagitrol V). Participants will be randomly assigned to 1 of the 2 treatment groups: Gynoclin V and Vagitrol V. Participants in Gynoclin V group will be administered 1 ovule (containing 80 milligram [mg] terconazole, 100 mg clindamycin and 0.5 mg fluocinolone acetonide) vaginally every 24 hours at night, for 3 days. Participants in the Vagitrol V group will be administered 1 ovule (containing 500 mg metronidazole, 0.5 mg fluocinolone acetonide and 100,000.00 microgram/milliliter nystatin) vaginally every 24 hours at night, for 10 days. Primarily, participants will be evaluated for signs and symptoms, characteristics of vaginal discharge, changes in vulvar region, changes in cervix and presence of bacteria, fungi and/or parasites. Participants' safety will be monitored throughout the study.
98 studies on the registry are indexed under Vaginitis; 12 are open to participants now.
This study's enrollment of 160 is above the median of 108 across 71 interventional studies indexed under Vaginitis.
Browse Vaginitis studies →Janssen-Cilag, S.A. is the lead sponsor of 21 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
One ovule containing 80 milligram (mg) terconazole, 100 mg clindamycin and 0.5 mg fluocinolone acetonide will be administered vaginally, every 24 hours at night, for 3 days.
Drug: Gynoclin V
One ovule containing 500 mg metronidazole, 0.5 mg fluocinolone acetonide and 100,000.00 microgram/milliliter nystatin will be administered vaginally, every 24 hours at night, for 10 days.
Drug: Vagitrol V
One ovule containing 80 milligram (mg) terconazole, 100 mg clindamycin and 0.5 mg fluocinolone acetonide will be administered vaginally, every 24 hours at night, for 3 days.
One ovule containing 500 mg metronidazole, 0.5 mg fluocinolone acetonide and 100,000.00 microgram/milliliter nystatin will be administered vaginally, every 24 hours at night, for 10 days.
Percentage of Participants With Presence or Absence of Symptoms 3 Days After Treatment
Participants were evaluated for presence or absence of symptoms (itching, burning and sudden vulvar pain) in response to treatment.
Time frame: 3 days after treatment (Day 7 for Gynoclin V or Day 13 for Vagitrol V)
Percentage of Participants With Presence or Absence of Symptoms 8 Days After Treatment
Participants were evaluated for presence or absence of symptoms (itching, burning and sudden vulvar pain) in response to treatment.
Time frame: 8 days after treatment (Day 12 for Gynoclin V or Day 18 for Vagitrol V)
Percentage of Participants With the Presence of Microorganisms (Single-celled, Tiny Organisms That Include Fungi, Bacteria, Viruses) 3 Days After Treatment
Percentage of participants with the presence of microorganisms (Candida albicans, Candida species, Gardnerella vaginalis, Vaginal flora, Lactobacillus species) in the wet mount, KOH, gram stain and vaginal discharge culture (candida and symptomatology) 3 days after treatment.
Time frame: 3 days after treatment (Day 7 for Gynoclin V or Day 13 for Vagitrol V)
Percentage of Participants With Response to Treatment Assessed by Participant
Response to treatment was evaluated by participant using a 5-point numerical scale: 1=No response (no improvement or condition even worsened); 2=Poor (No symptoms disappeared and symptoms are moderate to severe) 3=Moderate (improvement and symptoms are of moderate intensity); 4=Good (much improvement, but there are still some occasional mild symptoms); 5=Excellent (all symptoms disappeared).
Time frame: 8 days after treatment (Day 12 for Gynoclin V or Day 18 for Vagitrol V)
Percentage of Participants With Response to Treatment Assessed by Physician
Response to treatment was evaluated by Physician using a 5-point numerical scale: 1=No response (no improvement or condition even worsened); 2=Poor (No symptoms disappeared and symptoms are moderate to severe) 3=Moderate (improvement and symptoms are of moderate intensity); 4=Good (much improvement, but there are still some occasional mild symptoms); 5=Excellent (all symptoms disappeared).
Time frame: 8 days after treatment (Day 12 for Gynoclin V or Day 18 for Vagitrol V)
| Milestone | Gynoclin V (Terconazole+Clindamycin+Fluocinolone Acetonide) | Vagitrol V (Metronidazole+Fluocinolone Acetonide+Nystatin) |
|---|---|---|
| Started | 81 | 79 |
| Completed | 81 | 79 |
| Not completed | 0 | 0 |
Participants were evaluated for presence or absence of symptoms (itching, burning and sudden vulvar pain) in response to treatment.
| Percentage of Participants | Gynoclin V (Terconazole+Clindamycin+Fluocinolone Acetonide) | Vagitrol V (Metronidazole+Fluocinolone Acetonide+Nystatin) |
|---|---|---|
| Itching: Absent | 67.1 | 79.2 |
| Itching: Present | 32.9 | 20.8 |
| Burning: Absent | 78.5 | 88.3 |
| Burning: Present | 21.5 | 11.7 |
| Sudden vulvar pain: Absent | 95.0 | 90.9 |
| Sudden vulvar pain: Present | 5.0 | 9.1 |
Participants were evaluated for presence or absence of symptoms (itching, burning and sudden vulvar pain) in response to treatment.
| Percentage of Participants | Gynoclin V (Terconazole+Clindamycin+Fluocinolone Acetonide) | Vagitrol V (Metronidazole+Fluocinolone Acetonide+Nystatin) |
|---|---|---|
| Itching: Absent | 88.3 | 85.3 |
| Itching: Present | 11.7 | 14.7 |
| Burning: Absent | 93.5 | 92 |
| Burning: Present | 6.5 | 8 |
| Sudden vulvar pain: Absent | 97.4 | 89.3 |
| Sudden vulvar pain: Present | 2.6 | 10.7 |
Percentage of participants with the presence of microorganisms (Candida albicans, Candida species, Gardnerella vaginalis, Vaginal flora, Lactobacillus species) in the wet mount, KOH, gram stain and vaginal discharge culture (candida and symptomatology) 3 days after treatment.
| Percentage of Participants | Gynoclin V (Terconazole+Clindamycin+Fluocinolone Acetonide) | Vagitrol V (Metronidazole+Fluocinolone Acetonide+Nystatin) |
|---|---|---|
| Candida albicans | 2.5 | 0 |
| Candida species, Gardnerella vaginalis | 9.8 | 1.3 |
| Vaginal Flora | 55.6 | 58.2 |
| Lactobacillus species | 28.4 | 36.7 |
| No culture performed | 3.7 | 3.8 |
Response to treatment was evaluated by participant using a 5-point numerical scale: 1=No response (no improvement or condition even worsened); 2=Poor (No symptoms disappeared and symptoms are moderate to severe) 3=Moderate (improvement and symptoms are of moderate intensity); 4=Good (much improvement, but there are still some occasional mild symptoms); 5=Excellent (all symptoms disappeared).
| Percentage of Participants | Gynoclin V (Terconazole+Clindamycin+Fluocinolone Acetonide) | Vagitrol V (Metronidazole+Fluocinolone Acetonide+Nystatin) |
|---|---|---|
| Poor | 1.30 | 1.30 |
| Moderate | 0 | 4.00 |
| Good | 36.40 | 29.40 |
| Excellent | 62.30 | 65.30 |
Response to treatment was evaluated by Physician using a 5-point numerical scale: 1=No response (no improvement or condition even worsened); 2=Poor (No symptoms disappeared and symptoms are moderate to severe) 3=Moderate (improvement and symptoms are of moderate intensity); 4=Good (much improvement, but there are still some occasional mild symptoms); 5=Excellent (all symptoms disappeared).
| Percentage of Participants | Gynoclin V (Terconazole+Clindamycin+Fluocinolone Acetonide) | Vagitrol V (Metronidazole+Fluocinolone Acetonide+Nystatin) |
|---|---|---|
| Poor | 1.30 | 1.30 |
| Moderate | 0 | 5.30 |
| Good | 28.60 | 26.70 |
| Excellent | 70.10 | 66.70 |
Collected over Baseline up to Day 13 for Gynoclin V and Day 18 for Vagitrol V. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Gynoclin V (Terconazole+Clindamycin+Fluocinolone Acetonide) | — | 0/81 (0%) | 1/81 (1.2%) |
| Vagitrol V (Metronidazole+Fluocinolone Acetonide+Nystatin) | — | 0/79 (0%) | 1/79 (1.3%) |
| Event | Gynoclin V (Terconazole+Clindamycin+Fluocinolone Acetonide) | Vagitrol V (Metronidazole+Fluocinolone Acetonide+Nystatin) |
|---|---|---|
| Fungal InfectionsInfections and infestations | 0/81 | 1/79 |
| HeadacheNervous system disorders | 1/81 | 0/79 |
Participants who received at least 1 dose of study medication and who were evaluated for efficacy parameters were included in Intent-to-treat (ITT) population.
| Age Continuous(Years) | Gynoclin V (Terconazole+Clindamycin+Fluocinolone Acetonide) | Vagitrol V (Metronidazole+Fluocinolone Acetonide+Nystatin) | Total |
|---|---|---|---|
| Mean | 30.69 ± 7.17 | 30.56 ± 7.50 | 30.63 ± 7.33 |
| Sex: Female, Male(Participants) | Gynoclin V (Terconazole+Clindamycin+Fluocinolone Acetonide) | Vagitrol V (Metronidazole+Fluocinolone Acetonide+Nystatin) | Total |
|---|---|---|---|
| Female | 81 | 79 | 160 |
| Male | 0 | 0 | 0 |
The record gives a start of Dec 2007, a primary completion of Dec 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2013, 5 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.